Back to Search Start Over

Angiotensin Receptor Blockers and the Risk of Suspected Drug-Induced Liver Injury: A Retrospective Cohort Study Using Electronic Health Record-Based Common Data Model in South Korea.

Authors :
Kim H
Son N
Jeong D
Yoo M
Choi IY
Choi W
Chung YW
Ko SW
Byun S
Im S
Sim DW
Seo J
Kang MG
Lee JK
Seo YG
An HJ
Kim Y
Chae S
Jun DW
Chang DJ
Kim SG
Yi S
Yang HJ
Lee I
Park HJ
Lee JH
Kim B
Lee EE
Source :
Drug safety [Drug Saf] 2024 Jul; Vol. 47 (7), pp. 673-686. Date of Electronic Publication: 2024 Mar 21.
Publication Year :
2024

Abstract

Introduction: Angiotensin receptor blockers are widely used antihypertensive drugs in South Korea. In 2021, the Korea Ministry of Food and Drug Safety acknowledged the need for national compensation for a drug-induced liver injury (DILI) after azilsartan use. However, little is known regarding the association between angiotensin receptor blockers and DILI.<br />Objective: We conducted a retrospective cohort study in incident users of angiotensin receptor blockers from a common data model database (1 January, 2017-31 December, 2021) to compare the risk of DILI among specific angiotensin receptor blockers against valsartan.<br />Methods: Patients were assigned to treatment groups at cohort entry based on prescribed angiotensin receptor blockers. Drug-induced liver injury was operationally defined using the International DILI Expert Working Group criteria. Cox regression analyses were conducted to derive hazard ratios and the inverse probability of treatment weighting method was applied. All analyses were performed using R.<br />Results: In total, 229,881 angiotensin receptor blocker users from 20 university hospitals were included. Crude DILI incidence ranged from 15.6 to 82.8 per 1000 person-years in treatment groups, most were cholestatic and of mild severity. Overall, the risk of DILI was significantly lower in olmesartan users than in valsartan users (hazard ratio: 0.73 [95% confidence interval 0.55-0.96]). In monotherapy patients, the risk was significantly higher in azilsartan users than in valsartan users (hazard ratio: 6.55 [95% confidence interval 5.28-8.12]).<br />Conclusions: We found a significantly higher risk of suspected DILI in patients receiving azilsartan monotherapy compared with valsartan monotherapy. Our findings emphasize the utility of real-world evidence in advancing our understanding of adverse drug reactions in clinical practice.<br /> (© 2024. The Author(s).)

Details

Language :
English
ISSN :
1179-1942
Volume :
47
Issue :
7
Database :
MEDLINE
Journal :
Drug safety
Publication Type :
Academic Journal
Accession number :
38512445
Full Text :
https://doi.org/10.1007/s40264-024-01418-4